The “Intravenous (IV) Iron Drugs – Global Strategic Business Report” report has been added to Research and Markets’ offering.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
The report profiles 21 companies including many key and niche players such as:
– Allergan Plc. (Ireland)
– AMAG Pharmaceuticals, Inc. (USA)
– Daiichi Sankyo, Inc. (USA)
– Luitpold Pharmaceuticals, Inc. (USA)
– American Regent, Inc. (USA)
– Pharmacosmos A/S (Denmark)
– Sanofi US (USA)
– Vifor Pharma Ltd. (Switzerland)
– Vifor Fresenius Medical Care Renal Pharma (Switzerland)
Key Topics Covered:
1. Global Market Overview
2. Growth Drivers & Market Trends
3. Regulatory Overview
4. Overview Of Intravenous (IV) Iron Drugs
5. Recent Industry Activity
6. Focus On Select Players
7. Global Market Perspective
Total Companies Profiled: 21 (including Divisions/Subsidiaries 22)
– The United States (5)
– Japan (2)
– Europe (7)
– France (1)
– Germany (1)
– The United Kingdom (1)
– Rest of Europe (4)
– Asia-Pacific (Excluding Japan) (8)
For more information about this report visit https://www.researchandmarkets.com/research/2l58bv/intravenous_iv